BioNTech Reports €415M Q1 Loss, Focuses on Oncology Pipeline

BioNTech reported a wider net loss in the first quarter of 2025, with revenues declining slightly year-over-year, primarily due to reduced COVID-19 vaccine demand. Despite missing revenue expectations, the company’s loss per share was narrower than analysts anticipated, and BioNTech reaffirmed its 2025 revenue outlook of €1.7 billion to €2.2 billion, with sales expected to remain seasonally concentrated later in the year. The company highlighted strategic advancements in its oncology pipeline, focusing on two priority cancer programs—the bispecific antibody BNT327 and mRNA-based immunotherapies. BioNTech emphasized the shift in focus towards oncology as public policy, sentiment, and regulatory risks challenge its vaccine franchise. Leadership changes were also announced, with a new financial chief appointed to support BioNTech’s evolution into a multi-product oncology company by 2030. The company remains financially robust, maintaining a strong cash position despite ongoing challenges.